Press Releases

26 Aug 2024	PR Newswire	Actinogen announces further positive results on depression in the XanCIDD phase 2a trial
12 Aug 2024	PR Newswire	Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial
26 Jun 2024	PR Newswire	Positive Xanamem® biomarker trial published in the Journal of Alzheimer’s Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau
22 Apr 2024	PR Newswire	Enrolment completed in Actinogen’s XanaCIDD phase 2a cognition & depression trial
15 Apr 2024	PR Newswire	First patient treated in Actinogen’s XanaMIA phase 2b Alzheimer’s disease trial
24 Jan 2024	PR Newswire	Positive Xanamem® human PET study published in the Journal of Alzheimer’s Disease demonstrating robust CNS target enzyme occupancy
28 Nov 2023	PR Newswire	Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024
13 Oct 2023	PR Newswire	Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Boston
26 Sep 2023	PR Newswire	Actinogen optimizes XanaMIA Phase 2b Alzheimer’s disease trial design and provides general business update
07 Jun 2023	PR Newswire	Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
05 Jun 2023	Media	Insight: Beyond the amyloid hypothesis – how small molecules are giving hope to Alzheimer’s research
31 May 2023	PR Newswire	Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
30 Mar 2023	PR Newswire	Actinogen presents positive Phase 2a Xanamem data at AD/PD™ Alzheimer’s and Parkinson’s diseases conference
01 Mar 2023	Biotech Daily	Actinogen Appoints Nicki Vasquez Non-Executive Director
01 Feb 2023	Biotech Daily	Actinogen Appoints Dr Dana Hilt CMO
22 Dec 2022	PR Newswire	FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
14 Dec 2022	PR Newswire	Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
25 Nov 2022	Biotech Daily	Dr Boreham’s Crucible: Actinogen Medical
19 Oct 2022	Stockhead	Alzheimer’s drug no longer a moonshot as race heats up, ASX-listed Actinogen in the running
11 Oct 2022	EIN Presswire	Actinogen Medical (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer’s Disease (AD) patients
10 Oct 2022	Biotech Daily	Actinogen Xanamem Alzheimer’s Biomarker Effect
10 Oct 2022	PR Newswire	Actinogen Medical Limited (ACW) announces large Xanamem therapeutic effect in early-stage Alzheimer’s Disease (AD) patients
14 Jun 2022	Global Newswire	Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
27 Apr 2022	news.com.au	Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s
27 Apr 2022	The Australian	Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s
27 Apr 2022	Actinogen	Media Release: Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s by Aussie biotech Actinogen
11 Feb 2022	The Market Herald	Actinogen Medical (ASX:ACW) advances Alzheimer’s treatment
15 Jul 2021	The Market Herald	Actinogen Medical (ASX:ACW) enrols first patient in Alzheimer’s Disease trial
18 Jun 2021	Biotech Daily	Dr Boreham’s Crucible: Actinogen Medical
02 Jun 2021	The Market Herald	Actinogen Medical (ASX:ACW) granted ethics committee approval for Alzheimers study
02 Jun 2021	Biotech Daily	Actinogen: Part-A Xanamia Xanamem Cognition Trial Approved
22 Apr 2021	Biotech Daily	Actinogen Plans Three Phase II Cognition Trials For 2022
15 Mar 2021	Biotech Daily	Actinogen Appoints Dr Steven Gourlay CEO On $400k
11 Feb 2021	Biotech Daily	Actinogen Shortfall Raises $3.55m – Total $10.9m

Latest results

2024 Full Year Financial results

View Results Centre

2024 Annual General Meeting

Actinogen’s next Annual General Meeting

Date: 14 November 2024